Lege Artis Medicinae

[Titration of insulin glargin in type 2 diabetic patients treated with oral agents and with necessity of basal insulin in everyday medical practice ]

VÁNDORFI Győző, KOVÁCS GÁBOR

NOVEMBER 20, 2013

Lege Artis Medicinae - 2013;23(10-11)

[INTRODUCTION - Early insulin treatment is a widely accepted option for combination glucose-lowering therapy, and its most common form is basal insulin supported oral therapy (BOT). Due to its 24-hour action and lack of peaks in plasma insulin concentrations, insulin glargine is an ideal choice for BOT. METHODS - We conducted a prospective, non-interventional study to evaluate the efficiency and safety of dose titration, the period of time necessary to reach the target fasting blood glucose level, and the changes in glargine insulin dose. The study group included patients with type 2 diabetes who had been treated with insulin glargine in BOT regimen for no longer than four weeks. The follow-up period was six months. RESULTS - During the study period, the mean fasting plasma glucose was decreased from 9.8 mmol/L to 6.7 mmol/L, the mean HbA1c level decreased from 8.8% to 7.3%, and the mean postprandial glucose level decreased from 11.5 mmol/L to 8.2 mmol/L. Mild hypoglycaemic episodes occurred in 6.5% of patients in the first 3 months and in 6.9% of patients between months 3 and 6. During the same periods, severe hypoglycaemic episodes occurred in 0.08% and 0.17% of patients, respectively. Both mean body weight and mean BMI decreased during the study period. The average daily dose of glargine continuously increased during the observation period from baseline 10.42 IU to 17.69 IU. DISCUSSION - In the study population, glargine therapy in BOT regimen significantly improved glycaemic control, while a slight but statistically significant reduction was observed in the patients’ body weight. The daily dose of insulin glargine increased during titration, and the therapy proved to be safe.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Who are the happy female physicians in Hungary?]

GYŐRFFY Zsuzsa

[BACKGROUND - The female Physicians’ well-being and happiness has become the latest researching field of the “Physicians studies”. In Hungary the researches haven't focused on this subject. Our aim was to examine the subjective well-being of the Hungarian female Physicians. METHODS - Representative, cross-sectional, quantitative survey on a representative sample of female Physicians (N=408). Modified version of WHO Well- Being Index was performed to measure of subjective Well-Being. RESULTS - We have found that the key to the Hungarian female Physicians’ wellbeing is the “time”. Significantly higher rate of well-being is associated with reduced work-hours (8 hour or less, p=0.000), and duty hours (p=0.042), having one hour free time daily (p=0.021) and they satisfied with the time of doctor-patient interaction (p=0.021). The higher rate of Well-Being scores haven't associated with age, marital status, number of children and the speciality. CONCLUSION - Similarly to the national trends, the Hungarian female Physicians' well-being is depending on the work and the satisfaction with work. The satisfied healer is the key of the health system therefore the future studies and the prevention and intervention have to focus on the Physicians’ well-being.]

Lege Artis Medicinae

[Infection. Control?]

BARCS István

Lege Artis Medicinae

[Therapeutic options for the treatment of neuroendocrine tumors]

TÓTH Miklós

[This paper provides an overview of the latest clinical advances regarding state-of-theart treatment of neuroendocrine tumours. The first-line treatment of any localized neuroendocrine tumour is surgical removal of the tumour. The only exceptions are certain small gastric carcinoids and small, hormonally inactive pancreatic tumours associated with multiple endocrine neoplasia type I. The treatment strategies of disseminated neuroendocrine tumours should be based on a pathological diagnosis that uses the 2010 WHO classification (neuroendocrine tumours G1 and G2, neuroendocrine carcinoma G3). Debulking surgery and radiofrequency ablation can be used effectively not only as an anti-tumour treatment but also in patients with severe symptoms and hormone overproduction resistant to treatment. The use of somatostatin-analogs is considered to be standard treatment in functional neuroendocrine tumours of any origin, as well as in the anti-tumour therapy of G1/G2 small intestinal neuroendocrine tumours. For progressive G1-G2 neuroendocrine pancreatic tumours, streptozocin-based combined chemotherapy is the first-line treatment. Targeted drug therapies, such as mTOR inhibitors and tyrosine kinase inhibitors are used as second- or third-line agents in patients with inoperable pancreatic neuroendocrine tumours. Peptide receptor radiotherapy is increasingly used in Europe; however, its final place amongst other therapeutic modalities remains to be investigated.]

Lege Artis Medicinae

[Unparalleled Exhibitions in Budapest ]

NAGY Zsuzsanna

Lege Artis Medicinae

[The possibilities and practice of immunoglobulin replacement in adults with antibody deficiency]

KRIVÁN Gergely

[Primary antibody deficiencies can occur at any age, but in a significant number of patients the correct diagnosis has not been established yet and thus their treatment has not been initiated. In patients with primary antibody deficiency, lifelong immunoglobulin replacement therapy has no alternatives. Immunoglobulin replacement therapy applied at adequate doses can prevent infections and provide a good quality of life for patients. In addition to intravenous preparations that have been used for decades, new preparations for subcutaneous administration are available now in Hungary as well. Subcutaneous preparations have fewer systemic side effects, can be used at home and, with weekly infusions, can provide more constant IgG levels, which can be beneficial in preventing infections.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Antidiabetic therapy of patients with type 2 diabetes mellitus - The place of insulin administration]

GYIMESI András

[Nowadays numerous options to treat diabetes are available, and it is often difficult to choose the optimal treatment. This review summarises the options regarding insulin therapy of type 2 diabetes, in order to help the better management of patients in the everyday clinical practice.]

Lege Artis Medicinae

[THE ROLE OF ORAL ANTIDIABETIC AGENTS AND ACE INHIBITORS IN THE PREVENTION OF TYPE 2 DIABETES MELLITUS]

KEMPLER Péter

[Nowadays Type 2 diabetes is considered as a cardiovascular disease,. The cause of death among 80% of people with Type 2 diabetes is of cardiovascular origin, with the most common cause of death of myocardial infarction. Optimal solution would be the prevention of the disease and there are also some possibilities for intervention. The present paper summarises the role of antidiabetic agents and ACE inhibitors in the prevention of Type 2 diabetes mellitus. The incidence rate of Type 2 diabetes decreased by 36% using acarbose in the STOP NIDDM Trial and by 31% using metformin in the Diabetes Prevention Program. The rate of risk reduction regarding the incidence of Type 2 diabetes during the ALLHAT Study compared the subjects treated with thiazid diuretics among those treated with amlodipine was 25% by the end of the second year and 16% by the end of the fourth year, while the corresponding data for patients treated with lisinopril were 40% and 30%, respectively. The action of lisinopril on the better bioavailability of Insulin like growth factor I. (IGF-I) probably contributes to the beneficial effect of lisinopril on insulin sensitivity.]

Lege Artis Medicinae

[A remarkably successful therapy with gliclazid treatment in type 2 diabetes mellitus]

KIS János Tibor

[INTRODUCTION - Sulfonylureas have become sidelined as second-line preparations as their use has been associated with an increased occurrence of weight gain and hypoglykaemia. In the case reported, however, therapeutic goals have been achieved with the use of gliclazid. CASE REPORT - A 45-year-old man with type 2 diabetes mellitus was using a metformin XR preparation. His HbA1c level was high and his main complaint was distention. His abdominal complaint was also obstructing his diet. Because of the high HbA1c level and overweight I initiated incretin-mimetic treatment. Due to the worsening of abdominal complaints I replaced the treatment with gliclazid, after thoroughly informing the patient. With gliclazid treatment the patient's abdominal complaints subdued, he was able to maintain his diet, lost 14 kg in three months and the parameters of his carbohydrate metabolism normalised. CONCLUSION - In case of abdominal complaints, a repeated anamnesis of the diet can reveal metformin intolerance. In such cases, the use of gliclazid can lead to therapeutic success with no gastrointestinal adverse effects.]

Lege Artis Medicinae

[Inhibitors of the renal sodium-glucose cotransporter: possible new drug in armamentarium of diabetologists]

BECHER Péter, PATAI Árpád, MÁJER Katalin

[An important aim of diabetologists is prescribing modern antidiabetic drugs with not only glucose lowering but also an insulin sensitivity increasing property with weight loss without hypoglycaemic episodes and with positive effects on the pancreatic β-cells. A selective inhibition of the renal sodium-glucose cotransporter 2 protein leads to glucosuria, reduces HbA1c and body weight without hypoglycaemias. This benefits can also moderate the cardiovascular risk in diabetic patients. At the moment this molecules are under examination in different phase clinical studies. It seems that the first drug from this group for the clinical use will be the molecule dapagliflozin. The main side effect may be a vulvovaginal mycotic infection.]

Image challenge

What do you see on the feet of the diabetic patient?